AU2022426690A1 - Covariate correction for temporal data from phenotype measurements for different drug usage patterns - Google Patents

Covariate correction for temporal data from phenotype measurements for different drug usage patterns Download PDF

Info

Publication number
AU2022426690A1
AU2022426690A1 AU2022426690A AU2022426690A AU2022426690A1 AU 2022426690 A1 AU2022426690 A1 AU 2022426690A1 AU 2022426690 A AU2022426690 A AU 2022426690A AU 2022426690 A AU2022426690 A AU 2022426690A AU 2022426690 A1 AU2022426690 A1 AU 2022426690A1
Authority
AU
Australia
Prior art keywords
drug
phenotype
time points
covariate
computer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022426690A
Other languages
English (en)
Inventor
Kai-How FARH
Petko Plamenov Fiziev
Jeremy Francis Mcrae
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Illumina Inc
Original Assignee
Illumina Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Illumina Inc filed Critical Illumina Inc
Priority claimed from PCT/US2022/054196 external-priority patent/WO2023129622A1/en
Publication of AU2022426690A1 publication Critical patent/AU2022426690A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/10—Boolean models
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical & Material Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Pathology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ecology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
AU2022426690A 2021-12-29 2022-12-28 Covariate correction for temporal data from phenotype measurements for different drug usage patterns Pending AU2022426690A1 (en)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US202163294816P 2021-12-29 2021-12-29
US202163294828P 2021-12-29 2021-12-29
US202163294827P 2021-12-29 2021-12-29
US202163294820P 2021-12-29 2021-12-29
US202163294813P 2021-12-29 2021-12-29
US202163294830P 2021-12-29 2021-12-29
US63/294,827 2021-12-29
US63/294,813 2021-12-29
US63/294,820 2021-12-29
US63/294,830 2021-12-29
US63/294,828 2021-12-29
US63/294,816 2021-12-29
US202263351317P 2022-06-10 2022-06-10
US202263351299P 2022-06-10 2022-06-10
US202263351283P 2022-06-10 2022-06-10
US63/351,299 2022-06-10
US63/351,283 2022-06-10
US63/351,317 2022-06-10
US17/968,766 US20230207132A1 (en) 2021-12-29 2022-10-18 Covariate correction including drug use from temporal data
US17/968,766 2022-10-18
PCT/US2022/054196 WO2023129622A1 (en) 2021-12-29 2022-12-28 Covariate correction for temporal data from phenotype measurements for different drug usage patterns

Publications (1)

Publication Number Publication Date
AU2022426690A1 true AU2022426690A1 (en) 2024-07-04

Family

ID=86896998

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2022426690A Pending AU2022426690A1 (en) 2021-12-29 2022-12-28 Covariate correction for temporal data from phenotype measurements for different drug usage patterns
AU2022429829A Pending AU2022429829A1 (en) 2021-12-29 2022-12-28 Rare variant polygenic risk scores
AU2022425376A Pending AU2022425376A1 (en) 2021-12-29 2022-12-28 Optimized burden test based on nested t-tests that maximize separation between carriers and non-carriers

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022429829A Pending AU2022429829A1 (en) 2021-12-29 2022-12-28 Rare variant polygenic risk scores
AU2022425376A Pending AU2022425376A1 (en) 2021-12-29 2022-12-28 Optimized burden test based on nested t-tests that maximize separation between carriers and non-carriers

Country Status (7)

Country Link
US (3) US20230207132A1 (cg-RX-API-DMAC7.html)
EP (5) EP4457829B1 (cg-RX-API-DMAC7.html)
JP (3) JP2025502816A (cg-RX-API-DMAC7.html)
KR (3) KR20240124391A (cg-RX-API-DMAC7.html)
CN (3) CN118451511A (cg-RX-API-DMAC7.html)
AU (3) AU2022426690A1 (cg-RX-API-DMAC7.html)
CA (2) CA3242597A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120977385B (zh) * 2025-10-20 2026-02-06 浙江博圣生物技术股份有限公司 一种单基因遗传病致病突变的打分排序方法及系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1301633A1 (en) * 2000-07-21 2003-04-16 Althea Technologies, Inc. A systematic approach to mechanism-of-response analyses
WO2014110350A2 (en) * 2013-01-11 2014-07-17 Oslo Universitetssykehus Hf Systems and methods for identifying polymorphisms
CN111161799B (zh) * 2019-12-24 2023-12-15 大连海事大学 一种基于多组学数据获取多基因风险评分的方法及系统
WO2022020444A1 (en) * 2020-07-22 2022-01-27 Algen Biotechnologies, Inc. Methods and systems for determining drug effectiveness

Also Published As

Publication number Publication date
EP4457829C0 (en) 2026-02-04
CN118451511A (zh) 2024-08-06
EP4715828A2 (en) 2026-03-25
EP4457829B1 (en) 2026-02-04
US20230207052A1 (en) 2023-06-29
US20230207067A1 (en) 2023-06-29
KR20240131385A (ko) 2024-08-30
CN118451506A (zh) 2024-08-06
EP4457819A1 (en) 2024-11-06
KR20240124391A (ko) 2024-08-16
CN118475982A (zh) 2024-08-09
EP4742250A2 (en) 2026-05-13
EP4457818B1 (en) 2025-12-24
EP4457818C0 (en) 2025-12-24
JP2025502818A (ja) 2025-01-28
CA3242597A1 (en) 2025-02-26
JP2025502816A (ja) 2025-01-28
US20230207132A1 (en) 2023-06-29
JP2025502817A (ja) 2025-01-28
AU2022429829A1 (en) 2024-07-04
EP4457818A1 (en) 2024-11-06
EP4457829A1 (en) 2024-11-06
EP4715828A3 (en) 2026-06-17
AU2022425376A1 (en) 2024-06-27
KR20240124390A (ko) 2024-08-16
CA3242710A1 (en) 2023-07-06
EP4742250A3 (en) 2026-07-22

Similar Documents

Publication Publication Date Title
WO2023129621A1 (en) Rare variant polygenic risk scores
EP4413575A1 (en) Combined and transfer learning of a variant pathogenicity predictor using gapped and non-gapped protein samples
US20250201348A1 (en) Artificial intelligence-based detection of gene conservation and expression preservation at base resolution
US20250218534A1 (en) Artificial intelligence-based epigenetics at base resolution
EP4457829B1 (en) Covariate correction for temporal data from phenotype measurements for different drug usage patterns
US20240112751A1 (en) Copy number variation (cnv) breakpoint detection
US20230343413A1 (en) Protein structure-based protein language models
US20230108368A1 (en) Combined and transfer learning of a variant pathogenicity predictor using gapped and non-gapped protein samples
WO2023129622A1 (en) Covariate correction for temporal data from phenotype measurements for different drug usage patterns
WO2023129619A1 (en) Optimized burden test based on nested t-tests that maximize separation between carriers and non-carriers
Mohammed et al. Enhancing Hypertrophic Cardiomyopathy Heart Risk Assessment with Deep Learning and Multi-Omics Data Integration
WO2023059750A1 (en) Combined and transfer learning of a variant pathogenicity predictor using gapped and non-gapped protein samples
Nahlawi Increasing the Discovery Power and Confidence Levels of Disease Association Studies: A Survey
CN119920308A (zh) 一种预测细胞系特异功能性非编码变异的方法